Lord CJ - Search Results

1

A chemical inhibitor of PPM1D that selectively kills cells overexpressing PPM1D.

Rayter S, Elliott R, Travers J, Rowlands MG, Richardson TB, Boxall K, Jones K, Linardopoulos S, Workman P, Aherne W, Lord CJ, Ashworth A. Rayter S, et al. Among authors: lord cj. Oncogene. 2008 Feb 14;27(8):1036-44. doi: 10.1038/sj.onc.1210729. Epub 2007 Aug 13. Oncogene. 2008. PMID: 17700519

2

Phenotypic effects of heterozygosity for a BRCA2 mutation.

Warren M, Lord CJ, Masabanda J, Griffin D, Ashworth A. Warren M, et al. Among authors: lord cj. Hum Mol Genet. 2003 Oct 15;12(20):2645-56. doi: 10.1093/hmg/ddg277. Epub 2003 Aug 19. Hum Mol Genet. 2003. PMID: 12928478

3

DSS1 is required for RAD51 focus formation and genomic stability in mammalian cells.

Gudmundsdottir K, Lord CJ, Witt E, Tutt AN, Ashworth A. Gudmundsdottir K, et al. Among authors: lord cj. EMBO Rep. 2004 Oct;5(10):989-93. doi: 10.1038/sj.embor.7400255. Epub 2004 Sep 10. EMBO Rep. 2004. PMID: 15359272 Free PMC article.

4

Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy.

Farmer H, McCabe N, Lord CJ, Tutt AN, Johnson DA, Richardson TB, Santarosa M, Dillon KJ, Hickson I, Knights C, Martin NM, Jackson SP, Smith GC, Ashworth A. Farmer H, et al. Among authors: lord cj. Nature. 2005 Apr 14;434(7035):917-21. doi: 10.1038/nature03445. Nature. 2005. PMID: 15829967 Free article.

5

BRCA2-deficient CAPAN-1 cells are extremely sensitive to the inhibition of Poly (ADP-Ribose) polymerase: an issue of potency.

McCabe N, Lord CJ, Tutt AN, Martin NM, Smith GC, Ashworth A. McCabe N, et al. Among authors: lord cj. Cancer Biol Ther. 2005 Sep;4(9):934-6. doi: 10.4161/cbt.4.9.2141. Epub 2005 Sep 1. Cancer Biol Ther. 2005. PMID: 16251802

6

Interaction of the epidermal growth factor receptor and the DNA-dependent protein kinase pathway following gefitinib treatment.

Friedmann BJ, Caplin M, Savic B, Shah T, Lord CJ, Ashworth A, Hartley JA, Hochhauser D. Friedmann BJ, et al. Among authors: lord cj. Mol Cancer Ther. 2006 Feb;5(2):209-18. doi: 10.1158/1535-7163.MCT-05-0239. Mol Cancer Ther. 2006. PMID: 16505093 Free article.

7

Exploiting the DNA repair defect in BRCA mutant cells in the design of new therapeutic strategies for cancer.

Tutt AN, Lord CJ, McCabe N, Farmer H, Turner N, Martin NM, Jackson SP, Smith GC, Ashworth A. Tutt AN, et al. Among authors: lord cj. Cold Spring Harb Symp Quant Biol. 2005;70:139-48. doi: 10.1101/sqb.2005.70.012. Cold Spring Harb Symp Quant Biol. 2005. PMID: 16869747

8

Targeting the double-strand DNA break repair pathway as a therapeutic strategy.

Lord CJ, Garrett MD, Ashworth A. Lord CJ, et al. Clin Cancer Res. 2006 Aug 1;12(15):4463-8. doi: 10.1158/1078-0432.CCR-06-1269. Clin Cancer Res. 2006. PMID: 16899589 Review.

9

Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition.

McCabe N, Turner NC, Lord CJ, Kluzek K, Bialkowska A, Swift S, Giavara S, O'Connor MJ, Tutt AN, Zdzienicka MZ, Smith GC, Ashworth A. McCabe N, et al. Among authors: lord cj. Cancer Res. 2006 Aug 15;66(16):8109-15. doi: 10.1158/0008-5472.CAN-06-0140. Cancer Res. 2006. PMID: 16912188

10

RAD51, BRCA2 and DNA repair: a partial resolution.

Lord CJ, Ashworth A. Lord CJ, et al. Nat Struct Mol Biol. 2007 Jun;14(6):461-2. doi: 10.1038/nsmb0607-461. Nat Struct Mol Biol. 2007. PMID: 17549079 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

249 results

Search Page